Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Vision for Digital Health Transformation


Foreword by the Minister of Health

In the following pages, we reveal a compelling vision for the future of digital health in Lebanon—an innovative blueprint developed through collaborative, forward-thinking, and inclusive efforts. With the recognition of digital technology as an integral driver of healthcare improvement, the Ministry of Public Health (MoPH) has been at the forefront, rallying essential stakeholders and orchestrating strategic discussions aimed at redefining our healthcare landscape.

This grand vision is grounded in the National Health Strategy, launched by the MoPH in January 2023. Recognizing the importance of digital health transformation, this strategy identified it as a crucial pillar. From this sturdy foundation, the Digital Health Retreat was organized on May 18, 2023. This retreat acted as a catalyst, creating an arena for stakeholders to identify the challenges and opportunities present in Lebanon's digital health ecosystem. A consensus was reached, emphasizing the pressing need for a consolidated vision that enables our healthcare system and augments health outcomes for our people.

Our healthcare sector, while resilient, faces its fair share of hurdles. With this understanding, and building upon the significant investments in digital health stipulated by the National Health Strategy, our vision aims to utilize digital solutions to overcome these barriers, thereby enriching healthcare outcomes. This is a vision of synergy, empowerment, and readiness for the evolving landscape of healthcare.

Our transformative vision transcends policy constraints. It establishes a detailed blueprint for developing a resilient digital health infrastructure. These strategies encompass a multitude of aspects—from digital platforms and mobile applications to health information exchange systems and more.
The implications of this digital health transformation are immense. From improved care coordination to enhanced population health outcomes, this vision for digital health, inherent in the National Health Strategy, is poised to serve as a guiding beacon for our future. Our journey begins here, and we invite you to join us as we map the pathway for a healthier Lebanon. Together, we can transform this vision into reality.

Vision for Digital Health Transformation
    ...
    29
    ...
ATC Name B/G Ingredients Dosage Form Price
G04CA04 SILODOSINE ARROW G Silodosine - 4mg 4mg Capsule 732,394 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 0.5g 0.5g Injectable powder for solution+diluent 511,940 L.L
J01XA01 VANCO MEDIS 500MG G Vancomycin - 500mg 500mg Injectable powder for solution 998,475 L.L
L01AX03 TEMOZOLOMIDE ACCORD G Temozolomide - 5mg 5mg Capsule, hard 1,153,017 L.L
N02BE01 PARACETAMOL NORMON G Paracetamol - 1000mg/100ml 10mg/ml Injectable solution 9,633,134 L.L
N05AH03 OLIZAX 5 G Olanzapine - 5mg 5mg Tablet, mouth dissolving 1,466,580 L.L
N06BA09 PMS-ATOMOXETINE G Atomoxetine (HCl) - 40mg 40mg Capsule 4,706,136 L.L
R03BB01 IPRAVENT G Ipratropium bromide - 20mcg/2ml 20mcg/2ml Inhalation solution 630,262 L.L
A02BC02 GASTROPAN G Pantoprazole (sodium) - 20mg 20mg Tablet, enteric coated 568,445 L.L
A07XA04 RACECADOTRIL BGR G Racecadotril - 100mg 100mg Capsule 575,165 L.L
B05D CAPD/DPCA 17Solution for peritoneal dialysis stay safe G Sodium chloride - 5.786g/l, Sodium-(S)-lactate - 3.925g/l, Calcium chloride 2H2O - 0.1838g/l, Magnesium chloride, 6H2O - 0.1017g/l, Anhydrous glucose - 15g/l, Fructose , - up to 0.75g/l Injectable solution 605,921 L.L
C09CA06 CANDESARTAN BIOGARAN G Candesartan cilexetil - 32mg 32mg Tablet, scored 434,061 L.L
C10AA07 LIPIROSE OBP 20 G Rosuvastatin (calcium) - 20mg 20mg Tablet, film coated 639,925 L.L
G04CA04 SILODOSINE BIOGARAN G Silodosine - 4mg 4mg Capsule 555,007 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 0.5g 0.5g Injectable powder for solution 3,455,595 L.L
J01XA01 VANCOLON G Vancomycin (HCl) - 0.5g 0.5g Injectable lyophilised powder for solution 1,009,226 L.L
L01AX03 TEMOZOLOMIDE GP PHARM G Temozolomide - 5mg 5mg Capsule, hard 1,153,017 L.L
N02BE01 PARACETAMOL PANPHARMA G Paracetamol - 1000mg/100ml 10mg/ml Injectable solution 8,675,675 L.L
N05AH03 PRANZA G Olanzapine - 5mg 5mg Tablet, orodispersible 1,773,872 L.L
N06BA09 APO-ATOMOXETINE G Atomoxetine (HCl) - 25mg 25mg Capsule 3,703,630 L.L
S01CA02 LOXTRA G Prednisolone acetate - 2mg/ml, Tetrahydrozoline HCl - 0.4mg/ml, Ofloxacin - 3mg/ml Drops suspension 423,310 L.L
A02BC02 PANTO TAD G Pantoprazole (sodium) - 20mg 20mg Tablet, gastroresistant 294,302 L.L
A07XA04 RACECADOTRIL BIOGARAN CONSEIL G Racecadotril - 100mg 100mg Capsule 287,582 L.L
A11CC03 DERIL G Alfacalcidol - 1mcg 1mcg Capsule, soft 783,460 L.L
B05D CAPD/DPCA 19Solution for peritoneal dialysis stay safe G Sodium chloride - 5.786g/l, Sodium-(S)-lactate - 3.925g/l, Calcium chloride 2H2O - 0.1838g/l, Magnesium chloride, 6H2O - 0.1017g/l, Anhydrous glucose - 22.73g/l, Fructose , - up to 1.1g/l Injectable solution 740,031 L.L
C10AA07 PMS-ROSUVASTATIN G Rosuvastatin (calcium) - 20mg 20mg Tablet 564,414 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 0.5g 0.5g Injectable powder for solution+diluent 433,869 L.L
J01XA01 VANCOMYCIN HIKMA G Vancomycin (HCl) - 500mg 500mg Injectable powder for solution 998,475 L.L
L01AX04 DACARBAZINE MEDAC G Dacarbazine - 200mg 200mg Injectable powder for solution 15,866,076 L.L
M02AA10 ACHONID GEL G Ketoprofen - 2.5% 2.5% Gel 179,179 L.L
    ...
    29
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025